For: | Peng WT, Jiang C, Yang FL, Zhou NQ, Chen KY, Liu JQ, Peng SF, Fu L. Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study. World J Gastroenterol 2023; 29(44): 5907-5918 [PMID: 38111506 DOI: 10.3748/wjg.v29.i44.5907] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v29/i44/5907.htm |
Number | Citing Articles |
1 |
Yongzheng Hu, Yue Zhang, Wei Jiang. Targeting hepatitis B virus-associated nephropathy: efficacy and challenges of current antiviral treatments. Clinical and Experimental Medicine 2025; 25(1) doi: 10.1007/s10238-025-01584-4
|
2 |
Xinye Qiu, Yue Yin, Shibin Zhang, Wei Liu. Effectiveness and safety of tenofovir amibufenamide and tenofovir alafenamide in treating elderly patients diagnosed with decompensated hepatitis B cirrhosis: a retrospective cohort study. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1545108
|
3 |
Qing Zhang, Jianhua Xu, Dan Liu, Lilin Wang, Shan Ren, Sujun Zheng, Xinyue Chen, Li Qi, Junfeng Lu. Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study. Antiviral Therapy 2024; 29(5) doi: 10.1177/13596535241284226
|
4 |
Xinxin Rong, Guangde Yang, Yuanyuan Xu, He Chen, Xia Wang, Juanjuan Fu, Li Li, Xiucheng Pan. Efficacy and Safety of Tenofovir Amibufenamide and Tenofovir Alafenamide for First‐Time HBV‐Related Decompensated Cirrhosis. Journal of Viral Hepatitis 2025; 32(4) doi: 10.1111/jvh.14029
|
5 |
Ken Lin, Su-Wen Jiang, Ai-Rong Hu. Management of antiviral treatment for chronic hepatitis B patients with high viral load. World Chinese Journal of Digestology 2024; 32(9): 625 doi: 10.11569/wcjd.v32.i9.625
|
6 |
Chuang Jiang, Zhi-Hong Zhang, Jia-Xin Li. Current status of drug therapy for chronic hepatitis B. World Journal of Gastroenterology 2025; 31(2): 99443 doi: 10.3748/wjg.v31.i2.99443
|
7 |
Hai-Nan Ma, Kai-Sen Cao, Yan-Miao Liu, Cheng Chen, Hang Zhang, Fu-Shan Tang. Tenofovir amibufenamide: A potential alternative for chronic hepatitis B treatment. World Journal of Gastroenterology 2025; 31(10): 102580 doi: 10.3748/wjg.v31.i10.102580
|
8 |
Li-Yang Meng, Chao-Ting Yang, Jian-Feng Bao, Jin-Song Huang. Effectiveness and safety of tenofovir amibufenamide in chronic hepatitis B patients. World Journal of Gastroenterology 2024; 30(26): 3261-3263 doi: 10.3748/wjg.v30.i26.3261
|
9 |
Shenglong Lin, Wanlong Huang, Ziyuan Liao, Huaxi Ma, Wenjun Wu, Minghua Lin, Defu Huang, Haibing Gao. Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-78656-0
|